A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of Tofacitinib (Cp-690,550) In Chinese Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Conventional Synthetic Dmard
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 11 Jul 2019 Planned End Date changed from 26 Nov 2020 to 28 Feb 2021.
- 11 Jul 2019 Planned primary completion date changed from 26 Nov 2020 to 28 Feb 2021.
- 19 Sep 2018 Planned number of patients changed from 153 to 195.